GALT vs. CDXC, XNCR, KALV, EOLS, SANA, UPB, SAGE, ALT, TNGX, and KROS
Should you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include ChromaDex (CDXC), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Evolus (EOLS), Sana Biotechnology (SANA), Upstream Bio (UPB), Sage Therapeutics (SAGE), Altimmune (ALT), Tango Therapeutics (TNGX), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry.
Galectin Therapeutics vs. Its Competitors
ChromaDex (NASDAQ:CDXC) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.
ChromaDex has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.
ChromaDex currently has a consensus price target of $9.03, suggesting a potential upside of 0.00%. Galectin Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 178.42%. Given Galectin Therapeutics' higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than ChromaDex.
15.4% of ChromaDex shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 9.6% of ChromaDex shares are owned by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Galectin Therapeutics had 1 more articles in the media than ChromaDex. MarketBeat recorded 1 mentions for Galectin Therapeutics and 0 mentions for ChromaDex. Galectin Therapeutics' average media sentiment score of 1.05 beat ChromaDex's score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the news media.
ChromaDex has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks.
ChromaDex has a net margin of 1.62% compared to Galectin Therapeutics' net margin of 0.00%. ChromaDex's return on equity of 4.85% beat Galectin Therapeutics' return on equity.
Summary
ChromaDex beats Galectin Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Galectin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galectin Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GALT) was last updated on 7/3/2025 by MarketBeat.com Staff
